Blog Posts - Sovaldi



Watch: 2016 Newly Approved Hepatitis C Medications

Hepatitis C Cures: New Drugs and Treatment Discussed   Hepatitis C can now be cured. There are new FDA approved medicines to treat hepatitis C with over a 95% cure rate. Dr. Joseph Galati... Monday HCV News Ticker- Hepatitis C: Coffee, M...
by HCV New Drug Research on Jul 13, 2016

Evidence Review of Zepatier vs. Harvoni and Sovaldi for Hepatitis C

Evidence Review of Zepatier vs. Harvoni and Sovaldi for Hepatitis C Summary: Comparing 3 Direct-Acting Antiviral Agents for HCV: A Review of the Evidence Jackie Syrop Published Online: February 21,... Monday HCV News Ticker- Hepatitis C: Coffee, Me...
by HCV New Drug Research on Feb 21, 2016

Sovaldi - Pamela Anderson Opens Up About Hepatitis C Cure

ABC Breaking News | Latest News Videos Source - Sovaldi - Pamela Anderson Opens Up About Hepatitis C Cure Of Interest New Hepatitis C Fact Sheets: (Sovaldi, Olysio, Viekira Pak and Technivie,... Monday HCV News Ticker- Hepatitis C: Coffee, Med...
by HCV New Drug Research on Jan 27, 2016

Simeprevir + Sofosbuvir/OPTIMIST-1 Study Results Show Favorable HCV GT1 Combo Therapy

OPTIMIST-1 Study Results Show Favorable HCV GT1 Combo Therapy Treatment with simeprevir + sofosbuvir for 12 weeks was highly effective in patients with hepatitis C virus (HCV) genotype (GT) 1... Monday HCV News Ticker- Hepatitis C: Coffee, Medicare...
by HCV New Drug Research on Jan 22, 2016

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea Cho Y1, Cho EJ1, Lee JH1, Yu SJ1, Yoon JH1, Kim YJ1. CMH 2015... Monday HCV News Ticker- Hepatitis C: Coffee, Medicare, Awareness...
by HCV New Drug Research on Jan 18, 2016

Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort

Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort Niels Steinebrunner1, Martin F.... Monday HCV News Ticker- Hepatitis C: Coffee, Medica...
by HCV New Drug Research on Aug 5, 2015

Medivir announces Janssen submitted supplemental NDA to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir

Medivir announces that Janssen submitted supplemental New Drug Application to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir July 24, 2015 02:30 ET | Source: Medivir AB Stockholm,... Monday HCV News Ticker- Hepatitis C: Coffee,...
by HCV New Drug Research on Jul 24, 2015

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States Soumitri Barua; Robert Greenwald, JD; Jason Grebely, PhD; Gregory J. Dore,... Monday HCV News Ticker- Hepatitis C: Coffee, Me...
by HCV New Drug Research on Jun 30, 2015

Changing the face of hepatitis C management – the design and development of sofosbuvir

Changing the face of hepatitis C management – the design and development of sofosbuvir Authors Noell BC, Besur SV, deLemos AS Published Date April 2015 Volume 2015:9 Pages 2367—2374 DOI... Monday HCV News Ticker- Hepatitis C: Coffee, Medicare...
by HCV New Drug Research on May 21, 2015

Mylan launches hepatitis-C Sovaldi tablets in India

Mylan launches hepatitis-C Sovaldi tablets in India HYDERABAD: Pharma giant Mylan NV today said its subsidiary Mylan Pharmaceuticals has launched Gilead Sciences' Sovaldi (sofosbuvir 400mg tablets)... Monday HCV News Ticker- Hepatitis C: Coffee, Me...
by HCV New Drug Research on May 4, 2015

Egypt opens first factory for locally produced Sovaldi

Egypt opens first factory for locally produced Sovaldi Egypt's health minister said Hepatitis C is "one of the most dangerous threats to Egypt", on Sunday during the opening ceremony of a factory for... Monday HCV News Ticker- Hepatitis C: Coffee, M...
by HCV New Drug Research on May 4, 2015

EASL2015-Sofosbuvir Plus Ribavirin Provides High SVR at 12 Weeks in HCV Genotypes 2 and 3

Sofosbuvir Plus Ribavirin Provides High Sustained Virological Response at 12 Weeks in Patients With Hepatitis C Virus Genotypes 2 and 3: Presented at EASL By Chris Berrie VIENNA, Austria -- April... Monday HCV News Ticker- Hepatitis C: Coffee, Med...
by HCV New Drug Research on Apr 28, 2015

Geno 2-5: Gilead Results of Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5 -- High Cure Rates Observed Across a Range of Genotypes -- VIENNA,... Monday HCV News Ticker- Hepatitis C: Coffee, Medica...
by HCV New Drug Research on Apr 25, 2015

Natco Pharma gets nod to sell Hepatitis C medicine in India

Natco Pharma gets nod to sell Hepatitis C medicine in India By PTI Mar 12 2015 , New Delhi Natco Pharma has received approval from the national drug regulator for generic sofosbuvir tablets that... Monday HCV News Ticker- Hepatitis C: Coffee, Medi...
by HCV New Drug Research on Mar 12, 2015

$10 copy of Gilead’s blockbuster Sovaldi appears in Bangladesh

$10 copy of Gilead’s blockbuster Sovaldi appears in Bangladesh By Ketaki Gokhale and Makiko Kitamura / Bloomberg News March 8, 2015 11:27 PM MUMBAI, India — A $10 version of Sovaldi, the Gilead... Monday HCV News Ticker- Hepatitis C: Coffee,...
by HCV New Drug Research on Mar 9, 2015

NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C

Two new drug treatments for hepatitis C have been approved for NHS use by the National Institute for Health and Care Excellence. 25 February, 2015 | By Steve Ford NICE has recommended sofosbuvir... Monday HCV News Ticker- Hepatitis C: Coffee, Medica...
by HCV New Drug Research on Feb 25, 2015

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Frontline Gastroenterology Interferon-free Treatment for Genotypes 2 and 3 Patients With Hepatitis CNowlan Selvapatt, Philip HendyMedscape Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir and... Monday HCV News Ticker- Hepatitis C: Coffee, Medic...
by HCV New Drug Research on Feb 24, 2015

At $594 Per Dose Gilead Sciences, Inc. (GILD) Hepatitis Drug Is Too Costly For Veterans Affairs Department

At $594 Per Dose Gilead Sciences, Inc. (GILD) Hepatitis Drug Is Too Costly For Veterans Affairs Department BY LISA RAY · JANUARY 9, 2015 05:27 AM PST Gilead Sciences, Inc. (NASDAQ:GILD)‘s hepatitis... Monday HCV News Ticker- Hepatitis C: Coffee,...
by HCV New Drug Research on Jan 9, 2015

Gilead exclusive provider of hepatitis C medicine for CVS

Gilead exclusive provider of hepatitis C medicine for CVS By Robert Langreth and Caroline Chen BLOOMBERG NEWS JANUARY 05, 2015 Gilead Sciences Inc. was chosen over AbbVie Inc. as the main provider... Monday HCV News Ticker- Hepatitis C: Coffee, M...
by HCV New Drug Research on Jan 5, 2015

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

Source -  European  Pharmaceutical Review Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst The recent US Food and Drug Administration (FDA)... Monday HCV News Ticker- Hepatitis C: Coffee, Medica...
by HCV New Drug Research on Oct 22, 2014


Trending Topics

Close